JP Morgan Initiates Coverage On Praxis Precision Medicine with Overweight Rating, Announces Price Target of $700

JP Morgan analyst Tessa Romero has initiated coverage on Praxis Precision Medicine (NASDAQ: PRAX) with an Overweight rating. The firm has set a price target of $700 for the stock.